Acelrx pharmaceuticals announces revised merger agreement with tetraphase

Acelrx pharmaceuticals announces revised merger agreement with tetraphase.acelrx to acquire tetraphase for $37.0 million in stock and cash plus cvrs.tetraphase's board determined as a result of amendment to agreement, competing bidders' proposals were not superior.revised consideration includes up to $16.0 million in contingent value rights.tetraphase stockholders will receive, for each share of tetraphase stock $0.59 in cash and 0.7409 shares of acelrx stock.tetraphase's board determined as result of amendment to merger agreement, recommends merger agreement, to stockholders.
ACRX Ratings Summary
ACRX Quant Ranking